Key Takeaways
- Soft Q4, recovery narrative intact: Revenue fell 7.8% YoY as US biotech funding drought hit R&D services demand, but management points to a recent step-up in biotech funding as the leading indicator for a second-half recovery.
- Margins held despite the top-line miss: EBITDA margin expanded 298 bps YoY to 34.6% in Q4, aided by a one-off inventory provision reversal; full-year margin landed near the guided level at 29.1%.
- The biologics bet is now on the balance sheet: The Stelis facility acquisition closed, capex is fully funded from operating cash flow of ₹1,042 Cr, and repurposing stays on track for H2 2024.
- Dividend signal: The board recommended a final dividend of ₹1.25 per share, a 150% increase over the prior year's core dividend, signaling confidence in the balance sheet even as growth pauses.
- What to watch next quarter: Whether the biotech funding recovery actually converts into new R&D service orders, the pace of the Stelis facility qualification, and any margin impact as the inventory provision reversal drops out of the base.
Demand Environment
- US biotech funding freeze: Reduced demand for R&D services from US biotech clients, driven by a difficult funding environment, was the single identified driver of the Q4 revenue shortfall and the second-half slowdown.
- Recovery signal emerging: Management noted a recent step-up in new funding into US biotech and expects this to translate into R&D services demand and revenue growth in the latter part of FY25.
- Full-year resilience despite the drag: The broad operating span across discovery, development and manufacturing, plus a strong biologics performance, allowed the company to deliver 9.3% full-year revenue growth even as the second half weakened.
Hunt: "While the fourth quarter performance came in lower than expected, the underlying driver - reduced demand for research and development services within US biotech stemming from a difficult funding environment - is well understood and already showing positive signs of recovery."
Margin & Cost Structure
- Q4 margin expansion was partly one-off: EBITDA margin improved 298 bps YoY to 34.6%, driven by a 742 bps material cost improvement that included a ₹20.3 Cr reversal of inventory provisions created in prior quarters. Staff costs and other expenses both rose as a percentage of revenue.
- Full-year margin held near guided level: FY24 EBITDA margin declined 19 bps to 29.1%, with higher other expenses and depreciation offsetting gross margin gains. Management characterized this as delivering consistent operating leverage around the expected level.
- Tax tailwind boosted PAT: Q4 PAT rose 5.5% YoY despite the revenue decline, aided by a ₹23.2 Cr reversal of tax provisions from favourable assessment orders and interest income on an income tax refund.
Biologics Manufacturing Build-Out
- Stelis acquisition closed and funded: The acquisition of the multi-modal biologics manufacturing facility (Unit 3) from Stelis Biopharma was concluded in FY24, with transaction costs of 8.6 crore (net of tax) recorded as an exceptional item.
- Repurposing on schedule: Facility modifications and qualification are expected to complete in the second half of 2024; once operational, the site will offer both drug substance and drug product production. All quality-related digital platforms have already been extended to the facility.
- Capex fully self-funded: Net cash flow from operating activities of ₹1,042 Cr fully covered both the ongoing capex program and the Stelis acquisition, with non-current borrowings reduced sharply from 489 crore to 100 crore.
Biswas: "Our net cashflow generated from operating activities for the year was strong at Rs 1,042 Crores, which fully funded the capex and the acquisition of the biologics manufacturing plant."
Capability & Platform Investments
- New development services capability: A facility for purifying and separating chiral compounds and HPAPIs was operationalized in Q4, extending the company's ability to handle complex small-molecule development work.
- SynVent integrated discovery: Investment continued in the fully integrated therapeutic discovery and development platform covering oncology, gene therapy, CNS and pain management, spanning both small molecules and biologics.
- Syn.AI™ expansion beyond pharma: The AI platform's capabilities were expanded to identify effective drug targets, and the tool was applied to projects in the energy and cosmetic sectors, signaling cross-industry applicability.
Balance Sheet & Capital Allocation
- Equity strengthened: Total equity rose from 3,618 crore to 4,257.7 crore, while non-current borrowings fell sharply, reflecting the self-funded investment model.
- Capital work-in-progress surge: CWIP more than quadrupled from 176.9 crore to 836.8 crore, indicating significant ongoing capital expenditure that will convert to revenue-generating assets as projects commission.
- Dividend increase: The board recommended a final dividend of ₹1.25 per share, a 150% increase over the prior year's core dividend of 50 paise per share, subject to shareholder approval at the AGM.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | High single digits to low double digits, momentum building during the year | FY25 |
| EBITDA margin | Similar to FY24 level | FY25 |
| PAT growth | Single digits | FY25 |
| Stelis facility operational | Qualification and facility modifications complete; drug substance and drug product production | H2 2024 |
| Demand recovery | Recent US biotech funding step-up to drive R&D services demand recovery | Latter part of FY25 |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue from operations | ₹917 Cr, down 8% YoY |
| Reported revenue (incl. other income) | ₹933 Cr, down 8% YoY |
| Reported EBITDA | ₹333 Cr, down 1% YoY |
| EBITDA margin | 36%, up from 33% in Q4 FY23 |
| PAT before exceptional items | ₹189 Cr, up 6% YoY |
| PAT margin | 20%, up from 18% in Q4 FY23 |
| EBITDA from operations | ₹317 Cr, up 0.9% YoY |
| EBITDA from operations margin | 34.6%, up 298 bps YoY |
| EBIT from operations | ₹206 Cr, down 5.8% YoY |
| EBIT from operations margin | 22.5%, up 48 bps YoY |
| FY25 revenue growth guidance | High single digits to low double digits, momentum building during the year |
| FY25 EBITDA margin guidance | Similar to FY24 level |
| FY25 PAT growth guidance | Single digits |
| Final dividend per share | ₹1.25, up 150% over FY23 core dividend of 50 paise |
| Net cashflow from operating activities (FY24) | ₹1,042 Cr, fully funded capex and biologics plant acquisition |